Kovjazin R - Search Results

1

Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.

Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. Hardy B, et al. Among authors: kovjazin r. Hum Antibodies. 1997;8(2):95-8. Hum Antibodies. 1997. PMID: 9289394

2

A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.

Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. Hardy B, et al. Among authors: kovjazin r. Cancer Res. 1994 Nov 15;54(22):5793-6. Cancer Res. 1994. PMID: 7954401

3

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. Hardy B, et al. Among authors: kovjazin r. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5756-60. doi: 10.1073/pnas.94.11.5756. Proc Natl Acad Sci U S A. 1997. PMID: 9159146 Free PMC article.

4

Ferrocene-induced lymphocyte activation and anti-tumor activity is mediated by redox-sensitive signaling.

Kovjazin R, Eldar T, Patya M, Vanichkin A, Lander HM, Novogrodsky A. Kovjazin R, et al. FASEB J. 2003 Mar;17(3):467-9. doi: 10.1096/fj.02-0558fje. Epub 2003 Jan 2. FASEB J. 2003. PMID: 12514114

5

Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.

Kovjazin R, Horn G, Smorodinsky NI, Shapira MY, Carmon L. Kovjazin R, et al. PLoS One. 2014 Jan 8;9(1):e85400. doi: 10.1371/journal.pone.0085400. eCollection 2014. PLoS One. 2014. PMID: 24416403 Free PMC article.

6

Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S. Eren R, et al. Among authors: kovjazin r. J Virol. 2006 Mar;80(6):2654-64. doi: 10.1128/JVI.80.6.2654-2664.2006. J Virol. 2006. PMID: 16501075 Free PMC article.

7

ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.

Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, Horn G, Smorodinsky NI, Brenner B, Carmon L. Kovjazin R, et al. Vaccine. 2011 Jun 24;29(29-30):4676-86. doi: 10.1016/j.vaccine.2011.04.103. Epub 2011 May 12. Vaccine. 2011. PMID: 21570434

8

Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosis.

Kovjazin R, Dubnik A, Horn G, Smorodinsky NI, Hardan I, Shapira MY, Carmon L. Kovjazin R, et al. Exp Ther Med. 2012 Jun;3(6):1092-1098. doi: 10.3892/etm.2012.538. Epub 2012 Apr 3. Exp Ther Med. 2012. PMID: 22970023 Free PMC article.

9

The use of signal peptide domains as vaccine candidates.

Kovjazin R, Carmon L. Kovjazin R, et al. Hum Vaccin Immunother. 2014;10(9):2733-40. doi: 10.4161/21645515.2014.970916. Epub 2014 Oct 30. Hum Vaccin Immunother. 2014. PMID: 25483491 Free PMC article. Review.

10

Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.

Carmon L, Avivi I, Kovjazin R, Zuckerman T, Dray L, Gatt ME, Or R, Shapira MY. Carmon L, et al. Among authors: kovjazin r. Br J Haematol. 2015 Apr;169(1):44-56. doi: 10.1111/bjh.13245. Epub 2014 Dec 11. Br J Haematol. 2015. PMID: 25496030 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters